Data Support JANUMET™, an Investigational Combination Therapy of Sitagliptin Phosphate Plus Metformin for Type 2 Diabetes

Skin autofluorescence, as a measure of the accumulation of advanced glycation end products (AGEs) in tissue, may serve as an indicator of vascular damage in patients with type 2 diabetes, according to a new report.

In diabetic patients with hypertension, ACE inhibitors reduce the risk of developing diabetes-related kidney disease, independent of their effect in lowering blood pressure, reports a study in the December Journal of the American Society of Nephrology. “Our results clearly show that an ACE inhibitor should always be used in patients …

Digital Angel Corporation received patent approval for its syringe-implantable glucose-sensing RFID microchip, next is FDA approval. The RFID microchip measures the glucose concentration levels of diabetic patients. The syringe-implantable bio-sensor chip has a passive transponder, glucose sensor and integrated circuitry that allow anyone implanted with the microchip to painlessly scan …

Even if diabetes is left out of the equation, higher-than-optimum blood glucose is a major worldwide killer, equivalent to smoking deaths, according to researchers.

If Fluoride in our drinking water prevents cavities then why not statins? Statins found to reduce heart attacks by 29% and strokes by 14% in those without heart disease.

Jury is still out on Exubera.

Medication nonadherence was significantly associated with increased risks for all-cause hospitalization and for all-cause mortality.

Within weeks of Januvia being approved, Merck & Co. is ready to come out with a combination product of Januvia and metformin.

Actos is a drug used by millions of diabetics to control their blood may be valuable in preventing a common overlooked liver problem as well.